FY2019 · ended Dec 31, 2019 · Revenue $17,775, +9.0% YoY · Filed Feb 16, 2021
Bioforce Nanosciences Holdings, Inc. (BFNH) files with the SEC under industry code 3826, Laboratory Analytical Instruments.
Revenue
$17,775
+9.0% vs prior year
Net income
$-1.29M
-163.4% vs prior year
Operating cash flow (TTM)
$-41,934
+42.9% vs year-ago TTM
Free cash flow
—
EPS
$-0.04
-100.0% vs prior year
Dividend per share
None
Shares outstanding
33.52M
+0.0% vs prior year
Net cash
—
Operating margin
-261.8%
FY 2019
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- BFNH (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Virginia Beach, VA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1310488
- Former names
- SILVER RIVER VENTURES, INC. (until Feb 24, 2006)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Net income | -$1.3M | -$490,437 | -$471,953 | -$485,514 | -$501,955 |
| Diluted EPS | -$0.04 | -$0.02 | -$0.02 | — | — |
| Operating cash flow | -$65,150 | -$61,250 | -$46,702 | -$68,389 | -$77,772 |
| Total assets | $786 | $862 | $638 | $734 | $11,145 |
| Total liabilities | $619,329 | $2.3M | $1.8M | $1.3M | $873,008 |
| Stockholders' equity | -$618,543 | -$2.3M | -$1.8M | -$1.3M | -$861,863 |
| Cash and investments | $786 | $862 | $638 | $734 | $11,105 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 7, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Sep 4, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 18, 2026 | Aug 17, 2026 |
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 7, 2026 | Jul 1, 2026 |
All 253 Bioforce Nanosciences Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.